Zynerba Pharmaceuticals (Formerly AllTranz)
Pharmaceutical products via dermal solutions to treat a various neuroscience disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $200m Valuation: $200m -5.8x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (46858 %) | - | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (46408 %) | - | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 31680 % | - | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Zynerba Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative transdermal CBD therapies for patients with rare and near-rare neuropsychiatric disorders. The company's primary product candidate, Zygel, is a CBD gel designed to be applied to the skin, offering a non-invasive treatment option for conditions such as Fragile X Syndrome, Autism Spectrum Disorder, and 22q11.2 Deletion Syndrome. Zynerba operates in the biopharmaceutical market, targeting unmet medical needs in niche patient populations. The business model revolves around advancing clinical trials, securing regulatory approvals, and ultimately commercializing their therapies. Revenue generation is anticipated through product sales, partnerships, and potential licensing agreements.
Keywords: CBD therapies, neuropsychiatric disorders, transdermal gel, Fragile X Syndrome, Autism Spectrum Disorder, 22q11.2 Deletion Syndrome, clinical-stage, biopharmaceutical, niche markets, innovative treatments.